Guidelines for the clinical management of familial adenomatous polyposis (FAP)

Background: Familial adenomatous polyposis (FAP) is a well-described inherited syndrome, which is responsible for <1% of all colorectal cancer (CRC) cases. The syndrome is characterised by the development of hundreds to thousands of adenomas in the colorectum. Almost all patients will develop CRC if they are not identified and treated at an early stage. The syndrome is inherited as an autosomal dominant trait and caused by mutations in the APC gene. Recently, a second gene has been identified that also gives rise to colonic adenomatous polyposis, although the phenotype is less severe than typical FAP. The gene is the MUTYH gene and the inheritance is autosomal recessive. In April 2006 and February 2007, a workshop was organised in Mallorca by European experts on hereditary gastrointestinal cancer aiming to establish guidelines for the clinical management of FAP and to initiate collaborative studies. Thirty-one experts from nine European countries participated in these workshops. Prior to the meeting, various participants examined the most important management issues according to the latest publications. A systematic literature search using Pubmed and reference lists of retrieved articles, and manual searches of relevant articles, was performed. During the workshop, all recommendations were discussed in detail. Because most of the studies that form the basis for the recommendations were descriptive and/or retrospective in nature, many of them were based on expert opinion. The guidelines described herein may be helpful in the appropriate management of FAP families. In order to improve the care of these families further, prospective controlled studies should be undertaken.

[1]  Christopher Portier,et al.  Risk factors for childhood leukaemia. Discussion and summary. , 2008, Radiation protection dosimetry.

[2]  P. Propping,et al.  Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP) , 2007, Human mutation.

[3]  E. Bakker,et al.  Somatic APC mosaicism: an underestimated cause of polyposis coli , 2007, Gut.

[4]  H. Morreau,et al.  Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis , 2007, Clinical genetics.

[5]  D. Chung,et al.  Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  J. Gisbert,et al.  Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  J. Kleibeuker,et al.  Genotype-phenotype correlations as a guide in the management of familial adenomatous polyposis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  P. Møller,et al.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) , 2007, Journal of Medical Genetics.

[9]  S. Skapek,et al.  Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Nieuwenhuis,et al.  Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. , 2007, Critical reviews in oncology/hematology.

[11]  J. Baron,et al.  A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. , 2006, Gastroenterology.

[12]  P. Propping,et al.  Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? , 2006, Pediatric blood & cancer.

[13]  P. McGettigan,et al.  Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.

[14]  R. Phillips,et al.  A 10‐year review of surgery for desmoid disease associated with familial adenomatous polyposis , 2006, The British journal of surgery.

[15]  E. Kuipers,et al.  Duodenal carcinoma in MUTYH-associated polyposis , 2006, Journal of Clinical Pathology.

[16]  P. Propping,et al.  MUTYH‐associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype , 2006, International journal of cancer.

[17]  T. Athanasiou,et al.  Meta‐analysis of observational studies of ileorectal versus ileal pouch–anal anastomosis for familial adenomatous polyposis , 2006, The British journal of surgery.

[18]  E. Kuipers,et al.  Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP) , 2005, Journal of Medical Genetics.

[19]  J. Prendergast,et al.  Germline susceptibility to colorectal cancer due to base-excision repair gene defects. , 2005, American journal of human genetics.

[20]  M. Goggins,et al.  Prevention and management of duodenal polyps in familial adenomatous polyposis , 2005, Gut.

[21]  A. Tenesa,et al.  Re: Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. , 2005, Journal of the National Cancer Institute.

[22]  I. Tomlinson,et al.  Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation , 2004, Gut.

[23]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[24]  M. Leppert,et al.  Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. , 2004, Gastroenterology.

[25]  S. Clark,et al.  High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumors , 2004, Cancer.

[26]  P. Radice,et al.  Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas , 2004, International journal of cancer.

[27]  W. Bemelman,et al.  Adenocarcinoma in the anal canal after heal pouch-anal anastomosis for familial adenomatous polyposis using a double-stapled technique: Report of two cases , 2004, Diseases of the colon and rectum.

[28]  I. Christensen,et al.  Duodenal adenomatosis in familial adenomatous polyposis , 2004, Gut.

[29]  R. Écochard,et al.  Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Bülow,et al.  Results of national registration of familial adenomatous polyposis , 2003, Gut.

[31]  L. Lipton,et al.  Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. , 2003, The New England journal of medicine.

[32]  S. Laurberg,et al.  Female fecundity before and after operation for familial adenomatous polyposis , 2003, The British journal of surgery.

[33]  G. Aravantinos,et al.  The pharmacological treatment of aggressive fibromatosis: a systematic review. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  E. Boh,et al.  Cutaneous manifestations of gastrointestinal diseases. , 2002, Dermatologic clinics.

[35]  B. Levin,et al.  A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis , 2002, Gut.

[36]  A. Spigelman,et al.  Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study , 2002, Gut.

[37]  S. Piantadosi,et al.  Primary chemoprevention of familial adenomatous polyposis with sulindac , 2002 .

[38]  Alison L. Livingston,et al.  Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors , 2002, Nature Genetics.

[39]  F. Giardiello,et al.  Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. , 2001, Gastroenterology.

[40]  J. Gebert,et al.  Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families , 2001, Gut.

[41]  P. Radice,et al.  Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis , 2001, International journal of cancer.

[42]  S. Olschwang,et al.  Familial Adenomatous Polyposis: Prevalence of Adenomas in the Ileal Pouch After Restorative Proctocolectomy , 2001, Annals of surgery.

[43]  H. Järvinen,et al.  Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. , 2000, Gastroenterology.

[44]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[45]  H. Vasen When should endoscopic screening in familial adenomatous polyposis be started? , 2000, Gastroenterology.

[46]  P. Radice,et al.  Genotype and Phenotype Factors as Determinants for Rectal Stump Cancer in Patients With Familial Adenomatous Polyposis , 2000 .

[47]  Charles R. Thomas,et al.  Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors , 2000, Cancer.

[48]  H. Järvinen,et al.  Management of Duodenal Adenomas in 98 Patients with Familial Adenomatous Polyposis , 1999, Endoscopy.

[49]  J. Guillem,et al.  Cumulative risk of developing polyps or malignancy at the ileal pouch-anal anastomosis in patients with familial adenomatous polyposis , 1999, Journal of Gastrointestinal Surgery.

[50]  A. Fusco,et al.  Genetic Alterations in Thyroid Carcinoma Associated with Familial Adenomatous Polyposis: Clinical Implications and Suggestions for Early Detection , 1998, World Journal of Surgery.

[51]  H. Vasen,et al.  Occurrence of thyroid carcinoma in Dutch patients with familial adenomatous polyposis. An epidemiological study and report of new cases , 1998, European journal of gastroenterology & hepatology.

[52]  J. Church,et al.  Incidence of neoplastic polyps in the ileal pouch of patients with familial adenomatous polyposis after restorative proctocolectomy , 1998, Diseases of the colon and rectum.

[53]  S. Bülow,et al.  Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? , 1997, International Journal of Colorectal Disease.

[54]  S. Travis,et al.  Sweet's syndrome: an unusual cutaneous feature of Crohn's disease or ulcerative colitis. The South West Gastroenterology Group. , 1997, European journal of gastroenterology & hepatology.

[55]  E. Buskens,et al.  Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. , 1997, Gut.

[56]  A. Botha,et al.  Desmoids in familial adenomatous polyposis , 1997, The British journal of surgery.

[57]  G. Petersen,et al.  Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. , 1996, Gut.

[58]  C. Tops,et al.  Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis , 1996, The Lancet.

[59]  Z. Cohen,et al.  Changing causes of mortality in patients with familial adenomatous polyposis , 1996, Diseases of the colon and rectum.

[60]  R. Gardner,et al.  Familial adenomatous polyposis in a 5 year old child: a clinical, pathological, and molecular genetic study. , 1996, Journal of medical genetics.

[61]  S. Bülow,et al.  Centralized registration, prophylactic examination, and treatment results in improved prognosis in familial adenomatous polyposis. Results from the Danish Polyposis Register. , 1995, Scandinavian journal of gastroenterology.

[62]  K. Schmid,et al.  Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment , 1995, Diseases of the colon and rectum.

[63]  G. Thomas,et al.  Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. , 1995, Human molecular genetics.

[64]  H. Lynch,et al.  Rectal cancer after prolonged sulindac chemoprevention. A case report , 1995, Cancer.

[65]  C. Rossetti,et al.  Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee. , 1994, Seminars in surgical oncology.

[66]  G. Petersen,et al.  Desmoid tumours in familial adenomatous polyposis. , 1994, Gut.

[67]  A. Spigelman,et al.  Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis , 1993, Diseases of the colon and rectum.

[68]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[69]  I. Song,et al.  Risk of gastric cancer among Korean familial adenomatous polyposis patients , 1992, Diseases of the colon and rectum.

[70]  P. Vielh,et al.  Sulindac causes regression of rectal polyps in familial adenomatous polyposis. , 1991, Gastroenterology.

[71]  V. Fazio,et al.  Mortality in patients with familial adenomatous polyposis , 1990, Diseases of the colon and rectum.

[72]  G. Griffioen,et al.  The value of screening and central registration of families with familial adenomatous polyposis , 1990, Diseases of the colon and rectum.

[73]  A. Spigelman,et al.  UPPER GASTROINTESTINAL CANCER IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS , 1989, The Lancet.

[74]  Steffen Bülow Clinical features in familial polyposis coli , 1986, Diseases of the colon and rectum.

[75]  R. Coffey,et al.  Gastric adenocarcinoma complicating Gardner's syndrome in a North American woman. , 1985, Gastroenterology.

[76]  H. Järvinen,et al.  Finnish registry for familial adenomatosis coli. , 1984, Scandinavian journal of gastroenterology.

[77]  W. Waddell,et al.  Sulindac for polyposis of the colon , 1983, Journal of surgical oncology.

[78]  J. Jorizzo,et al.  Bowel-bypass syndrome without bowel bypass. Bowel-associated dermatosis-arthritis syndrome. , 1983, Archives of internal medicine.

[79]  F. Greenway,et al.  Cutaneous lesions after intestinal bypass. , 1980, Annals of internal medicine.

[80]  H. Bussey Familial polyposis coli. , 1975, Pathology annual.

[81]  E. Loizeau [Crohn's disease or ulcerative colitis?]. , 1969, Praxis.

[82]  J. J. Buckley,et al.  Report of Three Cases , 1962 .

[83]  H. Ikeuchi,et al.  Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  I. Blanco,et al.  [Familial adenomatous polyposis]. , 2006, Gastroenterologia y hepatologia.

[85]  S. Clark,et al.  Current ideas in desmoid tumours , 2005, Familial Cancer.

[86]  C. Sempoux,et al.  Restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis revisited , 2005, Familial Cancer.

[87]  S. Bülow,et al.  Desmoid tumour in familial adenomatous polyposis. A review of literature , 2004, Familial Cancer.

[88]  P. Propping,et al.  Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis , 2004, European Journal of Human Genetics.

[89]  J. Knight,et al.  Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. , 2004, Journal of the National Cancer Institute.

[90]  S. Bülow,et al.  Attenuated familial adenomatous polyposis (AFAP): a review of the literature , 2004, Familial Cancer.

[91]  A. Russo,et al.  Genotype and phenotype factors as determinants for rectal stump cancer in patients with familial adenomatous polyposis. Hereditary Colorectal Tumors Registry. , 2000, Annals of surgery.

[92]  H. Järvinen,et al.  Impact of screening examinations on survival in familial adenomatous polyposis. , 2000, Scandinavian journal of gastroenterology.

[93]  H. Kogelnik [Surgery versus radiotherapy for patients with aggressive fibromatosis or desmoid tumors. A comparative review of 22 articles]. , 2000, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[94]  J. Church,et al.  APC genotype, polyp number, and surgical options in familial adenomatous polyposis. , 1998, Annals of surgery.

[95]  H. Järvinen,et al.  Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment , 1996, International Journal of Colorectal Disease.

[96]  M. Bisgaard,et al.  Familial adenomatous polyposis (FAP): Frequency, penetrance, and mutation rate , 1994, Human mutation.

[97]  D. S. Santa Cruz,et al.  Neutrophilic dermatoses. , 1989, Seminars in dermatology.

[98]  T. Alm Surgical treatment of hereditary adenomatosis of the colon and rectum in Sweden during the last 20 years. Part II. Patients with prophylactic operations, primary and late results. Discussion and summary. , 1975, Acta chirurgica Scandinavica.